Beijing Beilu Pharmaceutical Co (SZSE:300016) ROCE % : 4.78% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Beijing Beilu Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beijing Beilu Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 4.78%.

Beijing Beilu Pharmaceutical Co ROCE % Historical Data

The historical data trend for Beijing Beilu Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Beilu Pharmaceutical Co ROCE % Chart

Beijing Beilu Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

14.57

8.93

6.50

1.28

-1.93

Beijing Beilu Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															3.57	0.88	0.34	-12.57	4.78

Beijing Beilu Pharmaceutical Co ROCE % Calculation

Beijing Beilu Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-48.017	/	( ( (2818.681 - 302.669)	+	(2819.424 - 359.17) )	/ 2 )
	=	-48.017	/	( (2516.012	+	2460.254)	/ 2 )
	=	-48.017	/	2488.133
	=	-1.93 %

Beijing Beilu Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	118.676	/	( ( (2819.424 - 359.17)	+	(2869.853 - 368.026) )	/ 2 )
	=	118.676	/	( ( 2460.254	+	2501.827 )	/ 2 )
	=	118.676	/	2481.0405
	=	4.78 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Beijing Beilu Pharmaceutical Co (SZSE:300016) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beijing Beilu Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Beijing Beilu Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Beilu Pharmaceutical Co (SZSE:300016) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Beilu Pharmaceutical Co Ltd (SZSE:300016) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

No. 3, Shuiyuan West Road, Miyun District, Beijing, CHN, 100082

Website

http://www.beilu.com.cn

Beijing Beilu Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of pharmaceutical products. The products of the company are contrasted agent series, psychotropic, and hypoglycemic products which include iopamidol injection, iodixanol injection, and reglinide tablets.

Executives

Zong Li	Directors, executives
Hong Cheng Jie	Director
Duan Xian Zhu	Directors, executives
Zhu Zhi	Director
Wang Dai Xue	Director
Li Hong	Directors, executives
Liu Ning	Directors, executives
Wu Rui Hua	Directors, executives
Wu Jie	Executives
Liu Dong Long	Supervisors
Hong Wei	Directors, executives

Beijing Beilu Pharmaceutical Co (SZSE:300016) Headlines

No Headlines